PortalPublikationenImpaired B-cell reconstitution in children after chemotherap...

Impaired B-cell reconstitution in children after chemotherapy for standard or medium risk acute precursor B-lymphoblastic leukemia

Standard

Impaired B-cell reconstitution in children after chemotherapy for standard or medium risk acute precursor B-lymphoblastic leukemia. / Wiegering, Verena; Frank, Jana; Freudenberg, Sandra; Morbach, Henner; Schlegel, Paul G; Eyrich, Matthias; Winkler, Beate.

in: LEUKEMIA LYMPHOMA, Jahrgang 55, Nr. 4, 04.2014, S. 870-875.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wiegering, V, Frank, J, Freudenberg, S, Morbach, H, Schlegel, PG, Eyrich, M & Winkler, B 2014, 'Impaired B-cell reconstitution in children after chemotherapy for standard or medium risk acute precursor B-lymphoblastic leukemia', LEUKEMIA LYMPHOMA, Jg. 55, Nr. 4, S. 870-875. https://doi.org/10.3109/10428194.2013.816423

APA

Wiegering, V., Frank, J., Freudenberg, S., Morbach, H., Schlegel, P. G., Eyrich, M., & Winkler, B. (2014). Impaired B-cell reconstitution in children after chemotherapy for standard or medium risk acute precursor B-lymphoblastic leukemia. LEUKEMIA LYMPHOMA, 55(4), 870-875. https://doi.org/10.3109/10428194.2013.816423

Vancouver

Wiegering V, Frank J, Freudenberg S, Morbach H, Schlegel PG, Eyrich M et al. Impaired B-cell reconstitution in children after chemotherapy for standard or medium risk acute precursor B-lymphoblastic leukemia. LEUKEMIA LYMPHOMA. 2014 Apr;55(4):870-875. https://doi.org/10.3109/10428194.2013.816423

Bibtex

@article{4f62a2dc909442c08bb5ea297dada6ee,
title = "Impaired B-cell reconstitution in children after chemotherapy for standard or medium risk acute precursor B-lymphoblastic leukemia",
abstract = "Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is a highly effective treatment, but at the same time causes significant suppression of the patient's immunity. Immune reconstitution was studied in a homogeneous cohort of 48 children with standard or medium risk ALL treated according to the ALL-Berlin-Frankfurt-M{\"u}nster (BFM) protocol. Whereas the T-cell compartment was only moderately affected and recovered to normal levels quickly after treatment cessation, B-cells were significantly reduced during and after therapy. In particular, the naive B-cell compartment declined. Even 5 years after the end of therapy, B-cell distribution was disturbed and patients showed an ongoing reconstitution. Thus, even standard regimens for chemotherapy cause severe B-cell depletion that resolves only gradually.",
keywords = "Adolescent, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Asparaginase/therapeutic use, B-Cell Activating Factor/metabolism, B-Lymphocyte Subsets/immunology, Biomarkers/metabolism, Child, Child, Preschool, Daunorubicin/therapeutic use, Female, Flow Cytometry, Follow-Up Studies, Humans, Immunophenotyping, Infant, Killer Cells, Natural/immunology, Male, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy, Prednisone/therapeutic use, T-Lymphocyte Subsets/immunology, Treatment Outcome, Vincristine/therapeutic use",
author = "Verena Wiegering and Jana Frank and Sandra Freudenberg and Henner Morbach and Schlegel, {Paul G} and Matthias Eyrich and Beate Winkler",
year = "2014",
month = apr,
doi = "10.3109/10428194.2013.816423",
language = "English",
volume = "55",
pages = "870--875",
journal = "LEUKEMIA LYMPHOMA",
issn = "1042-8194",
publisher = "informa healthcare",
number = "4",

}

RIS

TY - JOUR

T1 - Impaired B-cell reconstitution in children after chemotherapy for standard or medium risk acute precursor B-lymphoblastic leukemia

AU - Wiegering, Verena

AU - Frank, Jana

AU - Freudenberg, Sandra

AU - Morbach, Henner

AU - Schlegel, Paul G

AU - Eyrich, Matthias

AU - Winkler, Beate

PY - 2014/4

Y1 - 2014/4

N2 - Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is a highly effective treatment, but at the same time causes significant suppression of the patient's immunity. Immune reconstitution was studied in a homogeneous cohort of 48 children with standard or medium risk ALL treated according to the ALL-Berlin-Frankfurt-Münster (BFM) protocol. Whereas the T-cell compartment was only moderately affected and recovered to normal levels quickly after treatment cessation, B-cells were significantly reduced during and after therapy. In particular, the naive B-cell compartment declined. Even 5 years after the end of therapy, B-cell distribution was disturbed and patients showed an ongoing reconstitution. Thus, even standard regimens for chemotherapy cause severe B-cell depletion that resolves only gradually.

AB - Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is a highly effective treatment, but at the same time causes significant suppression of the patient's immunity. Immune reconstitution was studied in a homogeneous cohort of 48 children with standard or medium risk ALL treated according to the ALL-Berlin-Frankfurt-Münster (BFM) protocol. Whereas the T-cell compartment was only moderately affected and recovered to normal levels quickly after treatment cessation, B-cells were significantly reduced during and after therapy. In particular, the naive B-cell compartment declined. Even 5 years after the end of therapy, B-cell distribution was disturbed and patients showed an ongoing reconstitution. Thus, even standard regimens for chemotherapy cause severe B-cell depletion that resolves only gradually.

KW - Adolescent

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Asparaginase/therapeutic use

KW - B-Cell Activating Factor/metabolism

KW - B-Lymphocyte Subsets/immunology

KW - Biomarkers/metabolism

KW - Child

KW - Child, Preschool

KW - Daunorubicin/therapeutic use

KW - Female

KW - Flow Cytometry

KW - Follow-Up Studies

KW - Humans

KW - Immunophenotyping

KW - Infant

KW - Killer Cells, Natural/immunology

KW - Male

KW - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy

KW - Prednisone/therapeutic use

KW - T-Lymphocyte Subsets/immunology

KW - Treatment Outcome

KW - Vincristine/therapeutic use

U2 - 10.3109/10428194.2013.816423

DO - 10.3109/10428194.2013.816423

M3 - SCORING: Journal article

C2 - 23786458

VL - 55

SP - 870

EP - 875

JO - LEUKEMIA LYMPHOMA

JF - LEUKEMIA LYMPHOMA

SN - 1042-8194

IS - 4

ER -